The latest price target for Ovid Therapeutics (NASDAQ:OVID) was reported by HC Wainwright & Co. on September 30, 2024. The analyst firm set a price target for $3.00 expecting OVID to rise to within 12 months (a possible 183.02% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Ovid Therapeutics (NASDAQ:OVID) was provided by HC Wainwright & Co., and Ovid Therapeutics reiterated their buy rating.

There is no last upgrade for Ovid Therapeutics

There is no last downgrade for Ovid Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on September 30, 2024 so you should expect the next rating to be made available sometime around September 30, 2025.

While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a reiterated with a price target of $3.00 to $3.00. The current price Ovid Therapeutics (OVID) is trading at is $1.06, which is out of the analyst’s predicted range.